ArticleJournal of diabetes investigation2022
Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.
Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Frailty-related factors and 1-year renal function change after sodium-glucose cotransporter-2 inhibitors in elderly chronic kidney disease patients.Kidney research and clinical practice · 2026Article
- A novel prognostic model integrating host vulnerability and tumor biology for elderly patients with diffuse large B-cell lymphoma: the BAMAL score.Frontiers in oncology · 2026Article
- Chronic inflammation is not associated with attenuated sodium-glucose co-transporter 2 inhibitor-induced hemoglobin increase in patients with diabetes.Journal of diabetes investigation · 2026Article
- SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.International journal of molecular sciences · 2025Review
- Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study.Journal of diabetes research · 2025Observational
- Article
- Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors.American journal of epidemiology · 2024Article
- Modification Effects of Albuminuria on the Association Between Kidney Function and Development of Anemia in Diabetes.The Journal of clinical endocrinology and metabolism · 2024Article
- Review
- A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome.International journal of molecular sciences · 2023Review
- The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.Cardiovascular diabetology · 2022Review
- Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.Journal of diabetes investigation · 2022Article
- SGLT2 inhibitors: an evidence-based update on cardiovascular implications.Expert opinion on investigational drugsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
AIMS/
introductionSodium-glucose cotransporter 2 inhibitors (SGLT2i) were reported to increase hemoglobin levels in short-term clinical trials. Whether it is also true in real clinical practice is unknown. MATERIALS AND
methodsThis is a retrospective cohort study. Inclusion criterion was diabetes patients who visited our outpatient clinic from January 2019 to August 2020. Exposure of interest was the use of SGLT2i. Outcomes were hemoglobin levels. For the cross-sectional analyses, non-linear regression models were fitted with restricted cubic splines to investigate the association between hemoglobin levels and estimated glomerular filtration rate (eGFR) for users and non-users of SGLT2i. For the case-control study, cases (anemia defined as hemoglobin <120 g/L for men, <110 g/L for women or the use of erythropoiesis stimulating agents) and controls were matched by age, sex and eGFR.
resultsAmong 2,063 diabetes patients, 723 were taking SGLT2i. In the cross-sectional analyses, hemoglobin levels were higher among SGLT2i users compared with non-users at eGFR >15 mL/min/1.73 m
conclusionsThe use of SGLT2i was associated with higher hemoglobin levels and lower prevalence of anemia in real clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.